logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Halozyme, Inc.


USPTO Granted Patents = 85

% Expired Patents = 20.0



Trademarks = 6

Forward Citations = 1,518

Loading Chart...
Loading Chart...

63 inventors (with patents filed for the assignee):

goldMedal Gregory Ian Frost (38 out of 39 patents)

silverMedal Louis Howard Bookbinder (30 out of 30 patents)

bronzeMedal H Michael Shepard (29 out of 60 patents)

4.  Robert James Connor (27 out of 28 patents)

5.  Ge Wei (24 out of 25 patents)

6.  Anirban Kundu (23 out of 23 patents)

7.  Qiping Zhao (21 out of 21 patents)

8.  Kevin David Swanson (11 out of 31 patents)

9.  Baylor Frantz (9 out of 9 patents)

10.  Curtis B Thompson (8 out of 8 patents)

11.  Scott Beacher (8 out of 8 patents)

12.  David W Kang (6 out of 6 patents)

13.  Mike Travanty (6 out of 6 patents)

14.  Tara Nekoroski (6 out of 6 patents)

15.  Xiaoming Li (4 out of 19 patents)


Core Competencies:
Hyaluronidase
PH20 Polypeptide
Injection Device
Tumor Treatment
High Volume Administration
Glycosaminoglycanases
Combination Therapy
Super Fast-Acting Insulin
Soluble Glycoproteins
Adenosine Deaminase
Post-Prandial Glucose Control
Companion Diagnostics

85 patents:

1. 12678492 - COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES (2026-07-14),
2. 12636350 - Hyaluronidase Enzyme Formulations for High Volume Administration (2026-05-26),
3. 12600959 - PH20 polypeptide variants, formulations and uses thereof (2026-04-14),
4. 12582713 - METHODS OF TREATING TUMORS (2026-03-24),
5. D1118918 - Injector cap (2026-03-17),
6. D1118903 - Injection device (2026-03-17),
7. 12558404 - Hyaluronidase Enzyme Formulations for High Volume Administration (2026-02-24),
8. 12551539 - Hyaluronidase Enzyme Formulations for High Volume Administration (2026-02-17),
9. 12544429 - Hyaluronidase Enzyme Formulations for High Volume Administration (2026-02-10),
10. D1107901 - Injection device (2025-12-30),
11. D1105416 - Injection device (2025-12-09),
12. D1092725 - Injection device (2025-09-09),
13. 12371685 - PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof (2025-07-29),
14. 12264345 - PH20 polypeptide variants, formulations and uses thereof (2025-04-01),
15. 12195773 - PH20 polypeptide variants, formulations and uses thereof (2025-01-14),
Halozyme, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative therapies utilizing hyaluronidase enzymes. The company focuses on enhancing the delivery of biologics and improving patient outcomes through its proprietary PH20 polypeptide technology. Halozyme's research encompasses various applications, including tumor treatment, high-volume administration, and combination therapies, as well as advancements in super fast-acting insulin formulations. Its commitment to transforming therapeutic delivery positions it as a leader in the biopharmaceutical landscape.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Halozyme, Inc.
85 Patents

#74 in San Diego, CA

#1,012 in California

#4,373 in US

#8,944 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Halozyme, Inc.

Forward Citations = 1,518

63 inventors:

goldMedal Gregory Ian Frost (38 out of 39 patents)

silverMedal Louis Howard Bookbinder (30 out of 30 patents)

bronzeMedal H Michael Shepard (29 out of 60 patents)

4.  Robert James Connor (27 out of 28 patents)

5.  Ge Wei (24 out of 25 patents)

Please report any incorrect information to [email protected]
Loading…